Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x100px
Collaboration › Details

Merck (DE)–NMS Group: PARP inhibitor, 202209– collab + license option for PARP1 selective inhibitor NMS-293


Period Period 2022-09-21
Region Region ALL
Organisations Partner, 1st Merck KGaA
  Group Merck (DE) (Group)
  Partner, 2nd Nerviano Medical Sciences S.r.l. (NMS Srl)
  Group NMS Group (Group)
Products Product NMS-293 (NMS Group / Merck (DE))
  Product 2 drug development
Person Person Zazulina, Victoria (Merck (DE) 202209 Head of Development Unit Oncology before Boehringer Ingelheim)
Document Source Merck KGaA. (9/21/22). "Press Release: Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor [ Not intended for US- or Canada- and UK-based media ]". Darmstadt.

Record changed: 2022-11-19


Picture [iito] No Content Marketing 650x100px

More documents for Merck (DE) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top